Emergent BioSolutions Inc

Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate

22 Nov 2019 08:19:21 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day

21 Nov 2019 16:05:09 By Nasdaq GlobeNewswire

Emergent BioSolutions to Host 2019 Analyst and Investor Day

18 Nov 2019 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019

06 Nov 2019 16:05:05 By Nasdaq GlobeNewswire

Emergent BioSolutions to Host 2019 Analyst & Investor Day

21 Oct 2019 06:30:09 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate

10 Oct 2019 06:38:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019

09 Oct 2019 06:30:02 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder

27 Sep 2019 06:35:15 By Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference

26 Sep 2019 09:27:42 By Nasdaq GlobeNewswire

Emergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense

25 Sep 2019 16:15:01 By Nasdaq GlobeNewswire

Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile

03 Sep 2019 06:30:04 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: Emergent BioSolutions Inc

27 Aug 2019 12:40:01 By NetDania Notify

Emergent BioSolutions to Participate in Series of Investor Conferences

14 Aug 2019 16:15:23 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2019

01 Aug 2019 16:07:04 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile

30 Jul 2019 16:42:31 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Second Quarter 2019 Financial Results and Conduct a Conference Call on August 1, 2019

18 Jul 2019 06:30:01 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine

04 Jun 2019 16:05:30 By Nasdaq GlobeNewswire

Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness

03 Jun 2019 06:30:26 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: Emergent BioSolutions Inc

31 May 2019 09:45:02 By NetDania Notify

NetDania - New 12 months Low: Emergent BioSolutions Inc

30 May 2019 09:58:11 By NetDania Notify